Boehringer Ingelheim at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Boehringer Ingelheim brings 8 presentations to ObesityWeek 2026 in National Harbor, and exhibits at Booth 221, Suite 24, Suite 25. Its program centres on obesity and MASLD as linked metabolic diseases, and on measuring eating behavior from the patient's point of view. It covers validation of an eating behavior patient-reported measure in Europe and Japan and a long-acting NMUR2-GIPR dual agonist that adds weight loss through complementary satiety pathways.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Boehringer Ingelheim Ingelheim, Germany | ◆Gold Sponsor |
Family-owned pharmaceutical company developing treatments for obesity and MASH, including the glucagon and GLP-1 dual agonist survodutide. | Booth Exhibiting at Booth 221, Suite 24, Suite 25 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 3:30pm–3:45pm Poster Sat Nov 14 7:30pm–8:30pm Psychometric Validation of the Eating Behavior Patient-Reported Outcome Measure in Japan Nutrition, diet and food Poster Sat Nov 14 7:30pm–8:30pm Content Validation of the Eating Behavior Patient-Reported Outcome Measure in Japan Nutrition, diet and food Poster Sat Nov 14 7:30pm–8:30pm Talk Sun Nov 15 11:45am–1:15pm Bridging Obesity and MASLD Through Metabolic Dysfunction Links obesity, visceral and liver fat, and MASLD, making the case for waist measures and early liver checks, with patients describing their own experience. Metabolism and integrative physiologyChronic disease and obesity complications Poster Sun Nov 15 2:30pm–3:30pm Behavioral Phenotyping in Obesity Management: Insights from the Survodutide SYNCHRONIZE™-1 Trial Obesity pharmacotherapy and drug developmentInterventional and clinical studies Talk Sun Nov 15 6:30pm–8:30pm Clinical Case Files: Following the Metabolic Clues in Obesity and MASLD Case-based problem-solving on spotting MASLD risk early and coordinating liver and metabolic care for patients with obesity. Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications Talk Mon Nov 16 11:45am–12:45pm Glucagon’s Role in Metabolic Regulation and Why It Matters Covers how glucagon and the liver regulate glucose and fat metabolism and why this matters in obesity and related heart, kidney and metabolic diseases. Metabolism and integrative physiologyChronic disease and obesity complications |
Find decision makers at Boehringer Ingelheim
Tell us what you sell and we’ll find the people at Boehringer Ingelheim most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction